Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) COO Sells $296,636.65 in Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 6,865 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $43.21, for a total value of $296,636.65. Following the sale, the chief operating officer now directly owns 161,744 shares in the company, valued at approximately $6,988,958.24. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Patrick John Finn also recently made the following trade(s):

• On Monday, August 5th, Patrick John Finn sold 2,885 shares of Twist Bioscience stock. The shares were sold at an average price of $39.93, for a total value of $115,198.05.
• On Tuesday, July 23rd, Patrick John Finn sold 2,207 shares of Twist Bioscience stock. The stock was sold at an average price of $56.62, for a total value of $124,960.34.

Twist Bioscience Stock Performance

Twist Bioscience stock opened at $43.34 on Monday. Twist Bioscience Co. has a 1 year low of $14.42 and a 1 year high of $60.90. The firm’s 50 day moving average price is $44.94 and its two-hundred day moving average price is $43.75. The firm has a market cap of $2.52 billion, a price-to-earnings ratio of -12.90 and a beta of 1.77.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The company had revenue of $81.50 million during the quarter, compared to analyst estimates of $77.40 million. During the same quarter in the previous year, the firm earned ($1.01) earnings per share. The business’s revenue was up 27.7% compared to the same quarter last year. As a group, equities analysts predict that Twist Bioscience Co. will post -3.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on TWST. JPMorgan Chase & Co. upped their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. Evercore ISI upped their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Robert W. Baird raised their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research note on Monday, August 5th. The Goldman Sachs Group boosted their target price on Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, July 9th. Finally, Barclays decreased their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $51.63.

Institutional Trading of Twist Bioscience

Hedge funds have recently bought and sold shares of the company. EdgeRock Capital LLC purchased a new stake in shares of Twist Bioscience in the 2nd quarter valued at approximately $43,000. Blue Trust Inc. raised its stake in Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after purchasing an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale purchased a new stake in shares of Twist Bioscience in the second quarter valued at $61,000. Nisa Investment Advisors LLC boosted its position in shares of Twist Bioscience by 31.3% in the second quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock worth $113,000 after buying an additional 546 shares during the period. Finally, CWM LLC grew its holdings in shares of Twist Bioscience by 27.4% during the second quarter. CWM LLC now owns 2,437 shares of the company’s stock valued at $120,000 after buying an additional 524 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.